| abstract |
Refers to physiologically balanced injectable formulations of fosnetupitant; that are chemically stable for safety and efficacy. These formulations comprise: liquid or lyophilized fosnetupitant, or its pharmaceutically acceptable salts; optionally palonosetron or its pharmaceutically acceptable salt; sodium hydroxide; edetate disodium; optionally hydrochloric acid and mannitol. It is used for the treatment of diseases mediated by the rNK1 receptor, including nausea, emesis, among others. |